Release date: 2024-08-09 17:46:36 Article From: Lucius Laos Recommended: 110
Pemigatinib is a potent and selective oral antineoplastic drug targeting the FGFR subtype, primarily for the treatment of patients with advanced cholangiocarcinoma.
The price of Pemigatinib varies depending on factors such as region, specification, and manufacturer. The most circulating version on the market is the generic version produced by Lucius Pharmaceutical Co., Ltd., with a specification of 4.5mg*14 tablets and a price of 1,400 yuan, which may change with time, market changes, and policy adjustments.
Patients should follow the doctor's instructions at the time of purchase, and the doctor will make a comprehensive assessment based on the patient's condition, individual differences, and clinical data. When using generic drugs, patients should follow their doctor's advice and proceed with treatment under the guidance of their doctor.
The original drug invests a lot of money and time in the research and development process, and the price is high. Generic drugs, on the other hand, reduce costs by replicating the active ingredient and therapeutic effect of the original drug.
Market demand and availability in different regions can also affect the price of medicines.
Drug prices are also affected by national drug regulatory policies and medical insurance policies.
Before purchasing Pemigatinib, patients should fully understand the indications, dosage, adverse reactions, and precautions of the drug, and take the drug under the guidance of a doctor.
Patients can pay attention to the dynamic changes in drug prices and choose a version with a relatively reasonable price to purchase. At the same time, you can also pay attention to the changes in the medical insurance policy, so as to know whether the drug is included in the medical insurance catalog and obtain the corresponding reimbursement support.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: